Conference Coverage

VIDEO: New microscopy tools improve melanoma detection


 

AT SDEF HAWAII DERMATOLOGY SEMINAR

References

WAIKOLOA, HAWAII – Armed with dermoscopy and reflective confocal microscopy, dermatologists have been “pushing the envelope and becoming better and better at detecting melanoma and limiting the number of benign lesions being removed,” said Dr. Ashfaq A. Marghoob.

Dermoscopy – now used by about 75% of dermatologists in the United States – has lowered the benign-to-malignant ratio to about 5:1, Dr. Marghoob explained. That’s five benign nevi removed for every one melanoma found.

In an interview at the Hawaii Dermatology Seminar, Dr. Marghoob of Memorial Sloan Kettering Cancer Center, New York, discussed the impact that new technologies such as reflectance confocal microscopy are having on finding melanomas and differentiating them from benign nevi.

The Hawaii Dermatology Seminar is provided by the Global Academy for Medical Education/Skin Disease Education Foundation. The SDEF and this news organization are owned by the same parent company.

Dr. Marghoob had no disclosures.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

emechcatie@frontlinemedcom.com

Recommended Reading

EADV: Vismodegib treatment breaks don’t hurt efficacy
MDedge Hematology and Oncology
Sirolimus reduced posttransplant skin cancer risk
MDedge Hematology and Oncology
Encouraging results for MMS in digital melanoma cases
MDedge Hematology and Oncology
MAPK inhibitor combo offers prolonged survival from BRAF+ advanced melanoma
MDedge Hematology and Oncology
Anorectal melanoma rates rose significantly in 20-year analysis
MDedge Hematology and Oncology
Organ transplant recipients face increased risk of BCC
MDedge Hematology and Oncology
Dabrafenib may be useful in patients who discontinue vemurafenib
MDedge Hematology and Oncology
Who among us has not asked a patient to keep track of a mole?
MDedge Hematology and Oncology
High-dose interferon offered no survival benefit in patients with melanoma and a single tumor–positive sentinel lymph node
MDedge Hematology and Oncology
Second targeted combination regime approved for metastatic melanoma
MDedge Hematology and Oncology